Loading…
Chongqing-based pharmaceutical holding company selling drugs and health products in China.
Chongqing-based pharmaceutical holding company selling drugs and health products in China.
Moat: none
Headquarters: Chongqing, China · Employees: 12,237
Size C.Q. Pharmaceutical (000950.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.32B, the 1830th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.13 on 6 Nov 2026.
Performance Over six months the shares fell 11.6%, against -14.8% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 3.1% over the last twelve months (peer median +15.6%); the operating margin is 0.8% (peer median 2.9%).
Valuation It trades at 19.7× forward earnings against a peer median of 12.5× (3rd most expensive of 8).
Capital Return on invested capital runs 3.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥80.5B | CN¥82.3B | CN¥80.5B | CN¥78.3B | CN¥67.7B |
| Revenue growth | — | +2% | +3% | +16% | — |
| Gross profit | CN¥5.62B | CN¥5.40B | CN¥5.47B | CN¥5.73B | CN¥5.36B |
| EBITDA | n/a | CN¥1.54B | CN¥1.78B | CN¥2.35B | CN¥2.64B |
| Net income | CN¥323M | CN¥387M | CN¥283M | CN¥625M | CN¥952M |
| Free cash flow | -CN¥501M | CN¥544M | -CN¥371M | CN¥300M | CN¥40.9M |
| Capital expenditure | CN¥328M | CN¥300M | CN¥251M | CN¥244M | CN¥268M |
| Total debt | CN¥29.7B | CN¥28.1B | CN¥28.9B | CN¥27.2B | CN¥27.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000950.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.9% | -8.6% | 8th highest of 21 |
| 6-month return | -11.6% | -14.8% | 10th highest of 21 |
| Distance from 52-week high | -30.8% | -41.6% | 8th highest of 21 |
| Revenue growth (TTM) | -3.1% | +15.6% | 5th lowest of 17 |
| Operating margin | 0.8% | 2.9% | 8th lowest of 17 |
| Forward P/E | 19.7× | 12.5× | 3rd most expensive of 8 |
| ROIC minus cost of capital | -3.3 pp | -5.2 pp | 8th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 19.7× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% | -5.3% |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 12.5× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | n/a | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | n/a | 11.7% | +18.1% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |